XNCRXencor, Inc.
Price
+139%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, price roughly fair, growth fading, the market undecided.
We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb® drug candidates with improved properties and multi-target mechanisms of action.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Xencor, Inc. (XNCR) reported revenue of $51M in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with net loss of $22M. For the full year FY2025, revenue was $126M (+14% year on year) and net income −$92M. Its largest product in Q2 2026 was Royalty at $41M, 80% of the disclosed total, well ahead of Milestone at 20%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Xencor Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 29, 2026On July 29, 2026, Xencor, Inc. (the “Company”) entered into a settlement agreement and release (the “Settlement Agreement”), with Alexion Pharma International Operations Limited, an Irish limited company (“Alexion”) with respect to a commercial dispute related to U.S. royalties on Ultomiris® (ravulizumab-cwvz)Material agreement entered · Form 8-K
- May 6, 2026Xencor Reports First Quarter 2026 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $51.2MThe company’s own SEC segment disclosure.
- Royalty$41.2M80%
- Milestone$10.0M20%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.